Board to Meet on 7 October 2026 to Further Deliberate Proposed Acquisition of up to 60% in Meyonex Pharmaceuticals

Board meeting set for Wednesday, 07 October 2026.

Tue 29 Sep 2026

Board Meeting Date

Wednesday, 07 October 2026

Acquisition Target

Meyonex Pharmaceuticals Limited

Proposed Stake

up to 60% of equity share capital

Target Company Type

unlisted public company

Trading Window Closure

30 September 2026 till 48 hours after board meeting

What was shared

Tavexia Lifecare Limited (formerly Sattva Sukun Lifecare Limited) has intimated BSE under Regulation 29 that a meeting of its Board of Directors is scheduled for Wednesday, 07 October 2026.

Main agenda item

• To further discuss and deliberate upon the matter relating to the proposed acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an unlisted public company.
• To consider and transact any other business with the permission of the Chairperson.

Background

The matter is being taken up with reference to the earlier Board meeting held on 07 September 2026, at which the Board considered and approved the proposal for acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, and authorised designated representatives to undertake preliminary evaluation, due diligence, valuation and negotiations.

At the coming meeting, the Board will review developments in the matter and decide the further course of action on the proposed acquisition.

Trading window

In line with the Company's Code of Conduct on Insider Trading and SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons and their immediate relatives was closed from 30 September 2026 until 48 hours after the board meeting to be held for approval of the un-audited financial results for the half year ended 30 September 2026.

How to read this

This is an intimation of a scheduled meeting, not a completed transaction. The acquisition remains at the proposed stage, with evaluation, due diligence, valuation and negotiations underway. Investors may watch for the outcome disclosure after the meeting for details such as consideration, stake finally agreed and timelines.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.